EGFR and non-small cell lung carcinoma: The third-generation EGFR-TKI, osimertinib, is a mutant-selective EGFR inhibitor that can irreversibly inhibit NSCLC even in the presence of EGFR-sensitizing mutations and T790M resistance mutations.